Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTL CVE:GPH NYSEAMERICAN:IGC NASDAQ:KOD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTLArtelo Biosciences$1.08+5.9%$1.53$0.96▼$85.37$2.52M-0.11216,213 shs250,633 shsGPHGraphite OneC$0.95-1.0%C$1.09C$0.67▼C$2.57C$198.52M1.350961285,353 shs16,877 shsIGCIGC Pharma$0.27-2.5%$0.29$0.24▼$0.50$27.22M0.45496,598 shs457,941 shsKODKodiak Sciences$41.31+3.1%$36.86$4.32▼$47.84$2.59B2.19807,066 shs996,376 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTLArtelo Biosciences+5.88%-2.70%-16.92%-81.85%-98.33%GPHGraphite One-1.04%-5.00%-10.38%-24.00%+39.71%IGCIGC Pharma-2.51%-3.17%-3.20%-9.90%-18.81%KODKodiak Sciences+3.07%+7.19%+31.52%-4.18%+830.41%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTLArtelo Biosciences$1.08+5.9%$1.53$0.96▼$85.37$2.52M-0.11216,213 shs250,633 shsGPHGraphite OneC$0.95-1.0%C$1.09C$0.67▼C$2.57C$198.52M1.350961285,353 shs16,877 shsIGCIGC Pharma$0.27-2.5%$0.29$0.24▼$0.50$27.22M0.45496,598 shs457,941 shsKODKodiak Sciences$41.31+3.1%$36.86$4.32▼$47.84$2.59B2.19807,066 shs996,376 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTLArtelo Biosciences+5.88%-2.70%-16.92%-81.85%-98.33%GPHGraphite One-1.04%-5.00%-10.38%-24.00%+39.71%IGCIGC Pharma-2.51%-3.17%-3.20%-9.90%-18.81%KODKodiak Sciences+3.07%+7.19%+31.52%-4.18%+830.41%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTLArtelo Biosciences 1.67Reduce$54.004,900.00% UpsideGPHGraphite One 3.00BuyC$2.50163.16% UpsideIGCIGC Pharma 2.50Moderate Buy$5.501,922.06% UpsideKODKodiak Sciences 2.63Moderate Buy$42.142.02% UpsideCurrent Analyst Ratings BreakdownLatest KOD, GPH, IGC, and ARTL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2026GPHGraphite One Fundamental ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuyC$2.506/24/2026ARTLArtelo Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/8/2026IGCIGC Pharma Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.25 ➝ $5.505/11/2026KODKodiak Sciences Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$14.00 ➝ $61.00(Data available from 7/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTLArtelo BiosciencesN/AN/AN/AN/A($1.89) per shareN/AGPHGraphite OneN/AN/AC$0.01 per share94.17C$0.51 per shareN/AIGCIGC Pharma$1.27M21.44N/AN/A$0.08 per share3.40KODKodiak SciencesN/AN/AN/AN/A$2.97 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTLArtelo Biosciences-$12.88M-$32.74N/AN/AN/AN/A-1,600.12%-224.62%8/12/2026 (Estimated)GPHGraphite One-C$4.90M-C$0.07N/AN/AN/AN/A-14.13%-6.61%N/AIGCIGC PharmaN/A-$0.07N/AN/AN/AN/A-80.89%-63.75%N/AKODKodiak Sciences-$229.97M-$4.17N/AN/AN/AN/A-253.85%-81.48%8/12/2026 (Estimated)Latest KOD, GPH, IGC, and ARTL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026IGCIGC PharmaN/A-$0.02N/A-$0.02N/A$0.32 million5/14/2026Q1 2026ARTLArtelo Biosciences-$0.78-$4.00-$3.22-$4.00N/AN/A5/7/2026Q4 2025KODKodiak Sciences-$0.93-$0.94-$0.01-$0.94N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARTLArtelo BiosciencesN/AN/AN/AN/AN/AGPHGraphite OneN/AN/AN/AN/AN/AIGCIGC PharmaN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTLArtelo BiosciencesN/A1.791.79GPHGraphite One0.1330.040.33IGCIGC Pharma0.020.830.53KODKodiak SciencesN/A3.543.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTLArtelo Biosciences0.87%GPHGraphite One0.00%IGCIGC Pharma3.87%KODKodiak Sciences89.06%Insider OwnershipCompanyInsider OwnershipARTLArtelo Biosciences3.20%GPHGraphite One28.81%IGCIGC Pharma23.66%KODKodiak Sciences45.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTLArtelo Biosciences52.33 million2.26 millionNot OptionableGPHGraphite One20208.97 millionN/ANot OptionableIGCIGC Pharma61100.09 million76.41 millionN/AKODKodiak Sciences9062.58 million33.86 millionOptionableKOD, GPH, IGC, and ARTL HeadlinesRecent News About These CompaniesTraders Purchase Large Volume of Kodiak Sciences Call Options (NASDAQ:KOD)July 10 at 11:19 AM | marketbeat.comKodiak Sciences Inc. (NASDAQ:KOD) Receives Consensus Rating of "Moderate Buy" from AnalystsJuly 10 at 3:59 AM | americanbankingnews.comKodiak Sciences Inc.June 30, 2026 | barrons.com10 mid-cap US healthcare stocks with the strongest momentum gradesJune 24, 2026 | msn.comKodiak Sciences: Clinical Redemption Is Turning Into Platform LeverageJune 16, 2026 | seekingalpha.comKodiak CFO Sells $1 Million in Stock as Shares Surge 650%. What Investors Should KnowJune 9, 2026 | fool.comKodiak Sciences (KOD) Is Down 15.4% After Strong Zenkuda GLOW2 Data And Accelerated Filing PlansJune 7, 2026 | finance.yahoo.comKodiak Sciences Inc. (KOD) Presents at Jefferies Global Healthcare Conference 2026 - SlideshowJune 5, 2026 | seekingalpha.comKodiak Sciences Stockholders Back Directors and Governance ProposalsJune 4, 2026 | tipranks.comKodiak Stock Rises 35% in 3 Months: Here's What You Need to KnowJune 4, 2026 | zacks.comKodiak Sciences to Present at 2026 Jefferies Global Healthcare ConferenceMay 28, 2026 | prnewswire.comWhy One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping RallyMay 17, 2026 | fool.comKodiak Sciences (KOD) price target increased by 16.91% to 66.30May 14, 2026 | msn.comChardan Capital upgrades Kodiak Sciences (KOD)May 11, 2026 | msn.comA Look At Kodiak Sciences (KOD) Valuation After Positive Phase 3 GLOW2 Results For ZenkudaMay 11, 2026 | finance.yahoo.comZenkuda Phase 3 Win and Expanding Pipeline Might Change The Case For Investing In Kodiak Sciences (KOD)May 10, 2026 | finance.yahoo.comKodiak Sciences Inc.: Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial ResultsMay 8, 2026 | finanznachrichten.deKodiak's Q1 Loss Wider Than Expected, Pipeline Development in FocusMay 8, 2026 | zacks.comKodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial ResultsMay 7, 2026 | prnewswire.comKodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific ConferencesApril 30, 2026 | prnewswire.comKodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?April 30, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKOD, GPH, IGC, and ARTL Company DescriptionsArtelo Biosciences NASDAQ:ARTL$1.08 +0.06 (+5.88%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$1.10 +0.01 (+1.39%) As of 07/10/2026 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.Graphite One CVE:GPHC$0.95 -0.01 (-1.04%) As of 07/10/2026 03:59 PM EasternGraphite One Inc. operates as mineral exploration company in the United States. The company holds interest in the Graphite Creek property that consists of 135 mining claims located on the Seward Peninsula, Alaska. The company was formerly known as Graphite One Resources Inc. and changed its name to Graphite One Inc. in February 2019. Graphite One Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.IGC Pharma NYSEAMERICAN:IGC$0.27 -0.01 (-2.51%) Closing price 07/10/2026 04:10 PM EasternExtended Trading$0.27 +0.00 (+0.74%) As of 07/10/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.Kodiak Sciences NASDAQ:KOD$41.31 +1.23 (+3.07%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$41.99 +0.68 (+1.64%) As of 07/10/2026 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/06 - 07/10 Why WD-40 Is Proving Great Businesses Never Go Out of Style Rocket Lab’s Stock Drop Comes With a Bullish Twist Power Struggle: Wolfspeed Sues Navitas Over AI Chips Pushing the Edge: Super Micro Computer Reboots the AI Landscape Micron's $250 Billion Bet Could Reshape the AI Memory Race AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target IQM's Nasdaq Debut Could Change the Quantum Race for D-Wave Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
